Agenda features discussion of life sciences industry trends, business value of model-informed drug development strategies, and impact of generative AI on biosimulation and regulatory sciences
RADNOR, PA– April. 18, 2024 – Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will host the first-ever Certainty Conference. At this event, Certara clients will discuss examples of how modeling and biosimulation, AI, and scientific expertise are increasing the productivity of drug development. The two-day event held May 14-16, 2024, in Philadelphia, will assemble thought leaders across biosimulation, data and analytics, and regulatory sciences to discuss industry trends, share best practices, and future opportunities that will inform the next generation of personalized medicines.
At the conference, Dr. Scott Gottlieb, former commissioner of U.S. Food and Drug Administration and renowned expert on drug development, regulatory policy, and public health, will participate in a special fireside chat with Certara’s CEO Dr. William Feehery. The day and a half agenda features more than 50 speakers from across the industry, including Certara clients from over 20 biopharmaceutical companies as well as Certara experts named in the top 2% most-widely cited scientists by Elsevier BV and Stanford University.
“For over a decade, Certara has provided model-informed drug development solutions that help inform the development of safer and more effective medicines. Now, we’re integrating AI technology into our portfolio to further amplify the impact of biosimulation and its regulatory adoption,” said William F. Feehery, CEO of Certara.
The Certainty conference is designed for leaders in life sciences interested in applying model-informed drug development strategies to de-risk new therapies earlier and faster while advancing scientific insights. In addition to interdisciplinary plenary sessions and discussions from leaders across the industry, there are three tracks that attendees can choose from.
- The first track, “The Business Impact of Modeling and Biosimulation in Drug Development,” will provide an overview of how quantitative methods can better inform each decision, from discovery through to market access.
- The second track, “End-to-End Clinical Data Flow Automation,” will explore the new gold standards in automation and validation, which improve data quality and process efficiencies at every stage of the process.
- The final track, “Regulatory Sciences Strategy, Automation & Insights,” will share best practices for regulatory submissions and the impact of generative AI in assisting with regulatory submissions and medical writing.
Throughout the conference, Certara clients will share case studies, lessons learned, and outcomes from their experiences applying model-informed approaches to drug development. The agenda also features updates on the Certara vision, connected solutions and software platforms including the Certara.AI product for regulatory writing, CoAuthor.
For more information about Certainty, please visit https://certainty.certara.com/agenda/.
About Certara
Certara accelerates medicines using biosimulation software, technology and services to transform traditional drug discovery and development. Its clients include more than 2,400 biopharmaceutical companies, academic institutions, and regulatory agencies across 66 countries. Learn more at certara.com.
Certara Contact:
Sheila Rocchio
sheila.rocchio@certara.com
Media Contact:
Alyssa Horowitz
certara@pancomm.com